Loading stock data…
Heartflow, Inc. (HTFL)
$35.08-0.58 (-1.61%)
Market OpenUpdated 3:12 PM EDT
HeartFlow, Inc., a medical technology company, provides non-invasive solutions for diagnosing and managing coronary artery diseases the United States and worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Heartflow, Inc. in the Healthcare sector is trading at $35.08 with a market capitalization of $2.5B. Wall Street consensus targets $37.00 (6 analysts), implying a +5.5% move over the next 12 months. The stock is currently 15% below its 52-week high of $41.22, remaining 16.6% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +5.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $52.59M↑ | $49.13M↑ | $46.28M↑ | $43.42M↑ | $37.20M |
| Gross Profit | $42.16M↑ | $39.06M↑ | $35.41M↑ | $32.78M↑ | $27.94M |
| Operating Income | -$22.02M↓ | -$17.75M↓ | -$15.10M↓ | -$13.71M↑ | -$17.50M |
| Net Income | -$27.38M↓ | -$24.39M↑ | -$50.85M↓ | -$9.20M↑ | -$32.34M |
Peer Comparison
JNJUNHPFE
Fundamentals
HeartFlow, Inc., a medical technology company, provides non-invasive solutions for diagnosing and managing coronary artery diseases the United States and worldwide. Its HeartFlow Platform uses AI and computational fluid dynamics to creates a personal...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.49B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-39.14%
Volume
Today's trading volume
637,216
Recent News
HeartFlow vs. NovoCure: Which Emerging Healthcare Stock Is a Better Buy in 2026?
AI-powered diagnostics meet global oncology innovation as two medical disruptors post strong revenue growth, yet face distinct risk and valuation profiles.
A Look At HeartFlow (HTFL) Valuation As Analyst Fair Value Diverges From Current Share Price
Stock performance snapshot and recent trading context HeartFlow (HTFL) has drawn attention after recent trading, with the stock closing at US$28.10 and showing mixed short term moves. These include a decline over the past week and month, alongside a gain over the past 3 months. See our latest analysis for HeartFlow. For context, HeartFlow’s share price return has slipped over the year to date, but the 90 day share price return of 21.2% suggests earlier momentum that now appears to be fading...
Is HeartFlow Stock a Buy After an Institutional Investor Initiated a Position Worth $2.7 Million?
HeartFlow delivers AI-powered, non-invasive cardiac diagnostics for hospitals and cardiology clinics using proprietary imaging technology.
HeartFlow Inc (HTFL) Q1 2026 Earnings Call Highlights: Robust Revenue Growth and Raised ...
HeartFlow Inc (HTFL) reports a 41% revenue increase and raises full-year guidance, while navigating early-stage Plaque adoption and financial hurdles.
Heartflow Q1 Earnings Call Highlights
Heartflow (NASDAQ:HTFL) reported a sharply higher first-quarter revenue total and raised its full-year 2026 outlook, citing strength in its core FFRCT business, faster-than-expected adoption of its Plaque Analysis product and continued expansion of the coronary CT angiography, or CCTA, market. Pres